Acumen Pharmaceuticals Inc
ABOSHealthcare·Biotechnology·USA·Nano·NASD·Nov 13 • 6:34 AM ET
0.22+0.00 (0.46%)
2026-11-13 12:59 CET
Market cap
$15.81M
Revenue, TTM
0.00 USD m
Net income, TTM
-103.96 USD m
Free cash flow, TTM
-87.95 USD m
EPS diluted, TTM
-1.55
Price
ABOS against its 20, 50 and 200-day averagesPatternshover a marker to name it
93.9% under the 52-week high of 3.60 on 16 Mar 2026. 52-week low 0.19 on 5 Nov 2026. Last 15 sessions, 1219.4% high to low
Volume 0.05× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
ABOS52-week range, 1% of the way up
0.193.60
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.
| Index | RUT |
|---|---|
| Employees | 61 |
| IPO | Jul 01, 2021 |
| Beta | 0.45 |
| ATR, 14d | 0.17 |
| Rel volume | 0.05 |
| Short float | 7.38% |
| Insider own | 14.60% |
| Inst own | 59.01% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $15.81M |
| Enterprise Value | -36.48M |
| Income | -103.96M |
| Sales | 0.00M |
| Book / share | 0.48 |
| Cash / share | 1.09 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 61 |
| IPO | Jul 01, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 0.46 |
| Price / cash | 0.20 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 1.89 |
| Current Ratio | 1.89 |
| Debt / equity | 0.76 |
| Long-term debt / equity | 0.17 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.55 |
|---|---|
| Earnings next year | -0.75 |
| Earnings next quarter | -0.40 |
| Earnings this year | 23.15% |
| Earnings next year | 50.96% |
| Earnings growth, 5 years | 50.45% |
| Past earnings growth | -23.82% -61.49% |
| Past sales growth | - - |
| Earnings vs last year | 29.92% |
| Sales vs last year | - |
| Earnings vs last quarter | 19.67% |
| Sales vs last quarter | - |
| Earnings | Oct 26 BMO |
| Surprise | 9.93% - |
Ownership
| Insiders own | 14.60% |
|---|---|
| Insider trades | -0.37% |
| Institutions own | 59.01% |
| Institution trades | 3.46% |
| Return on assets | -91.28% |
| Return on equity | -162.72% |
| Return on capital | -256.84% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -79.70% |
| 50-day average | -88.17% |
| 200-day average | -90.91% |
Technical
| Shares out | 72.33M |
|---|---|
| Shares floating | 61.76M |
| Short / float | 7.38% |
| Short ratio | 1.82 |
| Short interest | 4.56M |
| 52-week high | 3.60 -93.9% |
| 52-week low | 0.19 +14.7% |
| Volatility | 7.95% 14.03% |
| Average range | 0.17 |
| Strength index | 21.49 |
| Market sensitivity | 0.45 |
| Relative volume | 0.05 |
| Avg Volume | 2.50M |
| Volume | 5,847 |
Performance
| Perf Week | -2.24% |
|---|---|
| Perf Month | -86.92% |
| Perf Quarter | -91.79% |
| Perf Half Y | -90.42% |
| Perf YTD | -89.64% |
| Perf Year | -87.93% |
| Perf 3Y | -89.24% |
| Perf 5Y | -98.31% |
| Perf 10Y | - |
| Recommendation | 3.20 |
| Target Price | 1.00 |
| Prev Close | 0.22 |
| Price | 0.22 |
| Change % | 0.23% |
Analyst ratings
latest 10 of 14| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 02, 2026 | Downgrade | BofA Securities | Buy → Underperform | $1 | +357.7% |
| Oct 30, 2026 | Downgrade | Stifel | Buy → Hold | $1 | +357.7% |
| Jun 17, 2025 | Initiated | Citigroup | Buy | $4 | +1,730.7% |
| Jul 26, 2024 | Initiated | Citigroup | Buy | $7 | +3,103.7% |
| Dec 12, 2023 | Initiated | Deutsche Bank | Buy | $8 | +3,561.3% |
| Jul 20, 2023 | Resumed | BofA Securities | Buy | $9 → $14 | +6,307.3% |
| May 18, 2023 | Initiated | Cantor Fitzgerald | Overweight | $13 | +5,849.7% |
| Jul 15, 2022 | Initiated | BTIG Research | Buy | $15 | +6,765.0% |
| Jun 30, 2022 | Initiated | H.C. Wainwright | Buy | $15 | +6,765.0% |
| Jan 21, 2022 | Upgrade | BofA Securities | Neutral → Buy | $16 → $14 | +6,307.3% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| PRTA | Prothena Corp Plc | 421.05M |
| ACIU | AC Immune SA | 217.80M |
| KRSA | Korsana Biosciences Inc | 1.42B |
| CGTX | Cognition Therapeutics Inc | 62.08M |
| ANVS | Annovis Bio Inc | 36.16M |
| AVXL | Anavex Life Sciences Corp | 93.62M |
| ALEC | Alector Inc | 378.07M |
| FLNA | Filana Therapeutics Inc | 22.12M |
| DNLI | Denali Therapeutics Inc | 3.03B |
| ALZN | Alzamend Neuro Inc | 6.17M |
Insider trading
latest 14 of 94| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Porter Derrell | Director | Jun 17 '26 | Option Exercise | 1.07 | 13,040 | 13,953 | 48,540 | Jun 17 05:10 PM |
| Porter Derrell | Director | Jun 15 '26 | Option Exercise | 1.07 | 6,460 | 6,912 | 54,760 | Jun 17 05:10 PM |
| Porter Derrell | Director | Jun 17 '26 | Sale | 2.33 | 13,040 | 30,318 | 35,500 | Jun 17 05:10 PM |
| Porter Derrell | Director | Jun 16 '26 | Sale | 2.33 | 12,800 | 29,773 | 35,500 | Jun 17 05:10 PM |
| Porter Derrell | Director | Jun 15 '26 | Sale | 2.35 | 6,460 | 15,149 | 48,300 | Jun 17 05:10 PM |
| DERRELL PORTER | Director | Jun 17 '26 | Proposed Sale | 2.33 | 13,040 | 30,323 | Jun 17 04:02 PM | |
| DERRELL PORTER | Director | Jun 16 '26 | Proposed Sale | 2.33 | 12,800 | 29,768 | Jun 16 05:03 PM | |
| DERRELL PORTER | Director | Jun 15 '26 | Proposed Sale | 2.35 | 6,460 | 15,149 | Jun 15 06:31 PM | |
| Fountain Nathan B | Director | Jun 09 '26 | Sale | 2.23 | 6,400 | 14,273 | 48,150 | Jun 10 04:51 PM |
| NATHAN FOUNTAIN | Director | Jun 09 '26 | Proposed Sale | 2.23 | 6,400 | 14,273 | Jun 09 04:15 PM | |
| Meisner Derek M | Chief Legal Officer & Corp Sec | Mar 06 '26 | Option Exercise | 1.85 | 2,090 | 3,866 | 176,089 | Mar 10 09:45 PM |
| Meisner Derek M | Chief Legal Officer & Corp Sec | Mar 06 '26 | Sale | 3.26 | 2,090 | 6,813 | 173,999 | Mar 10 09:45 PM |
| Meisner Derek M | Officer | Mar 06 '26 | Proposed Sale | 3.22 | 2,090 | 6,730 | Mar 06 04:51 PM | |
| Meisner Derek M | Chief Legal Officer & Corp Sec | Feb 27 '26 | Option Exercise | 1.85 | 9,406 | 17,401 | 183,405 | Mar 03 09:42 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VTWV | Vanguard Russell 2000 Value Index ETF | AUM: 1.29B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| BUSM | EA Bridgeway Ultra-Small Company Market ETF | AUM: 112.81M |
| VTHR | Vanguard Russell 3000 Index ETF | AUM: 4.87B |
News
latest 14 of 200- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint (GlobeNewswire) -90.83%
- Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer's Data Approach (InvestorsHub) +14.65%
- Acumen Beats On A Share-Count-Aided Loss, But November's Binary Sabirnetug Readout And A Thin Cash Runway Are The Real Story (Earnings Whispers)
- Acumen Pharmaceuticals beats Q3 estimates, shares jump 6% (Investing.com)
- Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
- Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
- Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 (GlobeNewswire) +13.84%
- Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 (GlobeNewswire)
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.16%
- Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ... (GuruFocus.com)
- Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
- Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 (GlobeNewswire)
- VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform (Exec Edge)
- Slate Medicines Appoints Mark W. Hahn to Board of Directors (Exec Edge)
Quarterly earnings
2026Q3 EPS -0.350 beat -0.389, from -0.440 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-10-26 08:30 | -0.350 | -0.389 | -0.350 | 0.00 | 0.00 | EPS -9.9% · sales - | vs 2025Q3, year-ago quarter · EPS -20.5% · sales - | 6 EPS · 4 sales | Open +7.58% vs SPY +0.30%. Close +14.65% vs SPY +0.71% |
| 2026Q2ended 2026-06-30 | 2026-08-12 08:30 | -0.450 | -0.359 | -0.453 | 0.00 | 0.00 | EPS +25.2% · sales - | vs 2025Q2, year-ago quarter · EPS -33.8% · sales - | 6 EPS · 4 sales | Open -2.43% vs SPY +0.54%. Close +1.62% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-12 08:30 | -0.330 | -0.403 | -0.328 | 0.00 | 0.00 | EPS -18.1% · sales - | vs 2025Q1, year-ago quarter · EPS -31.2% · sales - | 4 EPS · 2 sales | Open +0.39% vs SPY -0.33%. Close -3.50% vs SPY -0.15% |
| 2025Q4ended 2025-12-31 | 2026-03-26 08:30 | -0.400 | -0.453 | -0.415 | 0.00 | 0.00 | EPS -11.7% · sales - | vs 2024Q4, year-ago quarter · EPS -35.5% · sales - | 6 EPS · 3 sales | Open -2.66% vs SPY -0.72%. Close -3.04% vs SPY -1.79% |
| 2025Q3ended 2025-09-30 | 2025-11-12 08:30 | -0.440 | -0.603 | -0.437 | 0.00 | 0.00 | EPS -27.0% · sales - | vs 2024Q3, year-ago quarter · EPS -12.0% · sales - | 5 EPS · 3 sales | Open +0.51% vs SPY +0.26%. Close -1.02% vs SPY +0.06% |
| 2025Q2ended 2025-06-30 | 2025-08-12 08:30 | -0.680 | -0.489 | -0.676 | 0.00 | 0.00 | EPS +39.2% · sales - | vs 2024Q2, year-ago quarter · EPS +100.0% · sales - | 5 EPS · 2 sales | Open -0.70% vs SPY +0.37%. Close -11.27% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-13 08:30 | -0.480 | -0.726 | -0.476 | 0.00 | 0.00 | EPS -33.9% · sales - | vs 2024Q1, year-ago quarter · EPS +92.0% · sales - | 6 EPS · 1 sales | Open 0.00% vs SPY +0.07%. Close 0.00% vs SPY +0.66% |
| 2024Q4ended 2024-12-31 | 2025-03-27 08:30 | -0.620 | -0.514 | -0.618 | 0.00 | 0.00 | EPS +20.6% · sales - | vs 2023Q4, year-ago quarter · EPS +121.4% · sales - | 5 EPS · 2 sales | Open +7.76% vs SPY -0.25%. Close +6.03% vs SPY -0.27% |
| 2024Q3ended 2024-09-30 | 2024-11-12 08:30 | -0.500 | -0.362 | -0.495 | 0.00 | 0.00 | EPS +38.2% · sales - | vs 2023Q3, year-ago quarter · EPS +108.3% · sales - | 6 EPS · 2 sales | Open -0.62% vs SPY -0.01%. Close -16.93% vs SPY -0.31% |
| 2024Q2ended 2024-06-30 | 2024-08-13 08:30 | -0.340 | -0.280 | -0.342 | 0.00 | 0.00 | EPS +21.5% · sales - | vs 2023Q2, year-ago quarter · EPS +21.4% · sales - | 5 EPS · 1 sales | Open -2.34% vs SPY +0.61%. Close +8.20% vs SPY +1.64% |
| 2024Q1ended 2024-03-31 | 2024-05-14 08:30 | -0.250 | -0.261 | -0.249 | 0.00 | - | EPS -4.2% · sales - | vs 2023Q1, year-ago quarter · EPS -10.7% · sales - | 4 | Open +6.85% vs SPY +0.04%. Close +9.82% vs SPY +0.46% |
| 2023Q4ended 2023-12-31 | 2024-03-26 08:30 | -0.280 | -0.274 | -0.285 | - | 15.00 | EPS +2.3% · sales - | vs 2022Q4, year-ago quarter · EPS -12.5% · sales - | 5 EPS · 2 sales | Open -4.47% vs SPY +0.28%. Close -11.76% vs SPY -0.18% |
| 2023Q3ended 2023-09-30 | 2023-11-13 08:30 | -0.240 | -0.263 | -0.239 | 0.00 | 0.00 | EPS -8.6% · sales - | vs 2022Q3, year-ago quarter · EPS -7.7% · sales - | 5 EPS · 1 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-08 08:30 | -0.280 | -0.346 | -0.283 | 0.00 | 0.00 | EPS -19.1% · sales - | vs 2022Q2, year-ago quarter · EPS +12.0% · sales - | 5 EPS · 2 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-09 08:30 | -0.280 | -0.345 | -0.276 | 0.00 | 0.00 | EPS -18.9% · sales - | vs 2022Q1, year-ago quarter · EPS +21.7% · sales - | 4 EPS · 1 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-27 08:30 | -0.320 | -0.275 | -0.315 | 0.00 | 0.00 | EPS +16.3% · sales - | vs 2021Q4, year-ago quarter · EPS +96.9% · sales - | 4 EPS · 2 sales | - |
Annual earnings
2025FY EPS -2.000 beat -2.047, from -1.710 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2029FYestimate | - | -0.375 | - | - | 0.00 | - |
| 2028FYestimate | - | -0.243 | - | - | 0.00 | - |
| 2027FYestimate | - | -0.754 | - | - | 0.00 | - |
| 2026FYestimate | - | -1.537 | - | - | 0.00 | - |
| 2025FY | -2.000 | -2.047 | -2.000 | 0.00 | 0.00 | - |
| 2024FY | -1.710 | -1.604 | -1.705 | 0.00 | 0.00 | - |
| 2023FY | -1.080 | -1.072 | -1.077 | 0.00 | 7.50 | - |
| 2022FY | -1.060 | -1.011 | -1.056 | 0.00 | 0.00 | - |
| 2021FY | -5.020 | -3.453 | -2.486 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.54 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-05 | -1.54 | +1.5% |
| 2026Q4 | E | per share | 2026-11-05 | -0.40 | +5.6% |
| 2026FY | R | per share | 2026-11-05 | -1.49 | +1.3% |
| 2026Q4 | R | per share | 2026-11-05 | -0.37 | +5.5% |
| 2026FY | S | per share | 2026-11-05 | 0.00 | - |
| 2026Q3 | E | per share | 2026-10-26 | -0.39 | 0.0% |
| 2026Q3 | R | per share | 2026-10-26 | -0.40 | 0.0% |
| 2026Q4 | S | per share | 2026-10-26 | 0.00 | - |
| 2026Q3 | S | per share | 2026-08-12 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-28 | -0.36 | 0.0% |
| 2026Q2 | R | per share | 2026-07-26 | -0.34 | 0.0% |
| 2026Q2 | S | per share | 2026-06-03 | 0.00 | - |
| 2026Q1 | E | per share | 2026-04-02 | -0.40 | +7.8% |
| 2026Q1 | S | per share | 2026-04-02 | 0.00 | - |
| 2025FY | E | per share | 2026-03-26 | -2.04 | -0.2% |
| 2025Q4 | E | per share | 2026-03-26 | -0.46 | +1.5% |
| 2025FY | R | per share | 2026-03-26 | -2.00 | -1.1% |
| 2025Q4 | R | per share | 2026-03-26 | -0.41 | -5.1% |
| 2026Q1 | R | per share | 2026-03-26 | -0.37 | -3.9% |
| 2025FY | S | per share | 2026-03-26 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-26 | 0.00 | - |
| 2025Q3 | E | per share | 2025-10-26 | -0.60 | 0.0% |
| 2025Q3 | R | per share | 2025-10-26 | -0.58 | 0.0% |
| 2025Q3 | S | per share | 2025-08-25 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-01 | -0.49 | -0.1% |
| 2025Q2 | R | per share | 2025-07-28 | -0.52 | 0.0% |
| 2025Q2 | S | per share | 2025-06-17 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-04 | -0.73 | -2.8% |
| 2025Q1 | R | per share | 2025-04-04 | -0.76 | -4.5% |
| 2025Q1 | S | per share | 2025-03-27 | 0.00 | - |
| 2024FY | E | per share | 2025-03-26 | -1.60 | +1.5% |
| 2024Q4 | E | per share | 2025-03-26 | -0.51 | +4.5% |
| 2024FY | R | per share | 2025-03-26 | -1.64 | +1.9% |
| 2024Q4 | R | per share | 2025-03-26 | -0.55 | +5.3% |
| 2024FY | S | per share | 2024-11-22 | 0.00 | - |
| 2024Q4 | S | per share | 2024-11-12 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-28 | -0.36 | 0.0% |
| 2024Q3 | R | per share | 2024-10-28 | -0.39 | 0.0% |
| 2024Q3 | S | per share | 2024-08-14 | 0.00 | - |
| 2024Q2 | E | per share | 2024-07-31 | -0.27 | 0.0% |
| 2024Q2 | R | per share | 2024-07-31 | -0.30 | 0.0% |
| 2024Q2 | S | per share | 2024-07-25 | 0.00 | - |
| 2024Q1 | E | per share | 2024-05-10 | -0.26 | +0.2% |
| 2024Q1 | R | per share | 2024-04-04 | -0.28 | +0.8% |
| 2023FY | E | per share | 2024-03-08 | -1.07 | +13.0% |
| 2023FY | R | per share | 2024-03-08 | -1.07 | +16.9% |
| 2023FY | S | per share | 2024-01-12 | 7.50 | - |
| 2024Q1 | S | per share | 2023-11-13 | 0.00 | - |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.191 | -0.182 | -2.486 | -1.056 | -1.077 | -1.705 | -2.004 | -1.5466 | - |
| Sales USD millions | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 40 | 40 | 40 | 41 | 58 | 60 | 61 | - | 72 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.495 | -0.618 | -0.476 | -0.676 | -0.437 | -0.415 | -0.328 | -0.453 | -0.351 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 60 | 60 | 61 | 61 | 61 | 61 | 72 | 72 | 72 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.44-15.3% | 1.70 |
| Cost of Goods Sold Incl. D&A | 0.18 | 0.180.0% | 0.180.0% | 0.18+5.9% | 0.17 | 0.00 | - | - |
| Gross Profit | -0.18 | -0.18 | -0.18 | -0.18 | -0.17 | -0.00 | - | - |
| Selling, General and Administrative Excl. Other | 104.53 | 123.65+8.6% | 113.84+86.8% | 60.95+35.2% | 45.07+130.2% | 19.58+109.4% | 9.35-1.6% | 9.50 |
| Research and Development | 85.93 | 104.89+11.8% | 93.80+121.6% | 42.32+30.8% | 32.36+163.1% | 12.30+53.8% | 8.00-6.8% | 8.58 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -104.72 | -123.83 | -114.02 | -61.14 | -45.24 | -19.58 | -7.91 | -7.80 |
| Interest Expense | 4.25 | 4.22+3.7% | 4.07+601.7% | 0.58 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | -0.78 | 0.46 | -1.59-216.9% | 1.36 | 0.00-100.0% | 81.16 | -0.59-493.3% | 0.15 |
| Net Income Before Taxes | -103.96 | -121.33 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | -7.91 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -103.96 | -121.33 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | -7.91 |
| Net Income From Continuing Operations | -103.96 | -121.33 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | -7.91 |
| Net Income | -103.96 | -121.33 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | -7.69 |
| EPS (Recurring) per share | -1.45 | -2.00 | -1.72 | -1.06 | -1.06 | -1.08 | -0.19 | -0.19 |
| EPS (Basic, Before Extraordinaries) per share | -1.55 | -2.00 | -1.71 | -1.08 | -1.06 | -2.49 | -0.18 | -0.19 |
| EPS (Diluted) per share | -1.55 | -2.00 | -1.71 | -1.08 | -1.06 | -2.49 | -0.18 | -0.19 |
| EBITDA | -104.53 | -123.65 | -113.84 | -60.95 | -45.07 | -19.58 | -7.91 | -7.80 |
| Non-Operating Income (Expense) | 4.22 | 7.18-49.3% | 14.17+32.3% | 10.71+350.0% | 2.38+1600.0% | 0.14 | 0.00-100.0% | 0.04 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 10.04 | 9.85+2.3% | 9.63+56.8% | 6.14+100.7% | 3.06+232.6% | 0.92+513.3% | 0.15-11.8% | 0.17 |
| Operating Margin % | - | - | - | - | - | - | -550.97 | -459.93 |
| Net Margin % | - | - | - | - | - | - | -510.10 | -452.92 |
| Shares Outstanding million shares | 72.33 | 60.58+0.8% | 60.09+3.8% | 57.91+41.1% | 41.03+1.4% | 40.47+0.8% | 40.150.0% | 40.15 |
| Market Capitalization | 15.77 | 15.77-84.7% | 103.34-53.5% | 222.38+0.6% | 221.00-19.2% | 273.56-2.0% | 279.23 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.050.0% | 0.04-20.0% | 0.05+25.0% | 0.040.0% | 0.05+25.0% | 0.05+25.0% | 0.040.0% | 0.040.0% |
| Gross Profit | -0.05 | -0.04 | -0.05 | -0.04 | -0.05 | -0.05 | -0.04 | -0.04 |
| Selling, General and Administrative Excl. Other | 25.77-2.6% | 32.51-22.0% | 21.10-30.4% | 25.15-36.4% | 26.47-17.8% | 41.70+71.3% | 30.32+71.0% | 39.55+114.4% |
| Research and Development | 21.11-3.9% | 27.81-25.1% | 16.48-34.8% | 20.53-40.6% | 21.97-19.4% | 37.12+90.1% | 25.27+103.0% | 34.57+160.1% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.81 | -32.56 | -21.15 | -25.20 | -26.51 | -41.75 | -30.37 | -39.60 |
| Interest Expense | 1.00-6.5% | 1.09+3.8% | 1.07+4.9% | 1.09+4.8% | 1.07+3.9% | 1.05+5.0% | 1.02+2.0% | 1.04+79.3% |
| Unusual Expense | -0.65-247.7% | 0.16+300.0% | -0.46 | 0.17 | 0.44+4300.0% | 0.04 | -0.19-480.0% | -0.55-140.4% |
| Net Income Before Taxes | -25.37 | -32.72 | -20.74 | -25.14 | -26.45 | -40.95 | -28.80 | -37.15 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -25.37 | -32.72 | -20.74 | -25.14 | -26.45 | -40.95 | -28.80 | -37.15 |
| Net Income From Continuing Operations | -25.37 | -32.72 | -20.74 | -25.14 | -26.45 | -40.95 | -28.80 | -37.15 |
| Net Income | -25.37 | -32.72 | -20.74 | -25.14 | -26.45 | -40.95 | -28.80 | -37.15 |
| EPS (Recurring) per share | -0.36 | -0.45 | -0.33 | -0.41 | -0.43 | -0.68 | -0.48 | -0.62 |
| EPS (Basic, Before Extraordinaries) per share | -0.35 | -0.45 | -0.33 | -0.41 | -0.44 | -0.68 | -0.48 | -0.62 |
| EPS (Diluted) per share | -0.35 | -0.45 | -0.33 | -0.41 | -0.44 | -0.68 | -0.48 | -0.62 |
| EBITDA | -25.77 | -32.51 | -21.10 | -25.15 | -26.47 | -41.70 | -30.32 | -39.55 |
| Non-Operating Income (Expense) | 0.79-49.7% | 1.09-42.3% | 1.02-57.7% | 1.32-54.9% | 1.57-55.6% | 1.89-49.6% | 2.41-39.0% | 2.93-25.4% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 2.71+10.2% | 2.52+0.8% | 2.40-2.8% | 2.42+3.4% | 2.46+5.1% | 2.50+1.2% | 2.47-0.4% | 2.34+43.6% |
| Shares Outstanding million shares | 72.33+19.4% | 72.31+19.4% | 72.23+19.3% | 60.58+0.8% | 60.57+0.8% | 60.57+0.8% | 60.57+0.8% | 60.09+3.8% |
| Market Capitalization | 15.77-84.8% | 192.85+174.4% | 170.42+157.9% | 127.81+23.7% | 103.58-30.5% | 70.27-51.7% | 66.09-71.8% | 103.34-53.5% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 116.86-31.9% | 171.56-29.5% | 243.52+37.1% | 177.60-8.6% | 194.24+343.7% | 43.78+568.4% | 6.55 |
| Short Term Receivables | 0.62+55.0% | 0.40+73.9% | 0.23 | 0.00 | 0.00-100.0% | 0.11+266.7% | 0.03 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.76-25.0% | 6.35+121.3% | 2.87+5.5% | 2.72-38.5% | 4.42+718.5% | 0.54-10.0% | 0.60 |
| Total Current Assets | 122.25-31.4% | 178.31-27.7% | 246.62+36.8% | 180.33-9.2% | 198.66+347.1% | 44.43+518.8% | 7.18 |
| Net Property, Plant & Equipment | 0.24-29.4% | 0.34-32.0% | 0.50+85.2% | 0.27+575.0% | 0.04 | 0.00 | 0.00 |
| Total Investments and Advances | 0.23-99.6% | 60.20-4.1% | 62.79+296.4% | 15.84-75.0% | 63.24 | 0.00 | 0.00 |
| Long-Term Note Receivable | - | 0.00 | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - | 0.00 | 0.00 |
| Deferred Tax Assets | 0.16 | - | - | - | - | - | - |
| Other Assets | 0.11-26.7% | 0.15-31.8% | 0.22+46.7% | 0.15+1400.0% | 0.01 | 0.00-100.0% | 0.14 |
| Total Assets | 123.00-48.5% | 238.99-22.9% | 310.12+57.7% | 196.59-14.6% | 230.33+418.4% | 44.43+507.0% | 7.32 |
| Short Term Debt Incl. Current Port. of LT Debt | 8.91+6753.8% | 0.13-85.1% | 0.87+770.0% | 0.10 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.55-90.3% | 5.65+309.4% | 1.38-15.9% | 1.64+50.5% | 1.09+105.7% | 0.53+140.9% | 0.22 |
| Other Current Liabilities | 20.54-5.9% | 21.83+103.4% | 10.73+76.8% | 6.07+49.5% | 4.06-30.5% | 5.84+421.4% | 1.12 |
| Total Current Liabilities | 30.01+8.7% | 27.61+112.9% | 12.97+66.1% | 7.81+51.7% | 5.15-19.2% | 6.37+375.4% | 1.34 |
| Long Term Debt | 22.40-24.2% | 29.57-2.0% | 30.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 0.16 | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 52.57-8.1% | 57.18+32.5% | 43.15+452.5% | 7.81+51.7% | 5.15-19.2% | 6.37+375.4% | 1.34 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 56.65+225.6% | 17.40 |
| Common Equity | 70.43-61.3% | 181.82-31.9% | 266.97+41.4% | 188.78-16.2% | 225.18 | -18.59 | -11.42 |
| Total Shareholders Equity | 70.43-61.3% | 181.82-31.9% | 266.97+41.4% | 188.78-16.2% | 225.18+491.6% | 38.06+536.5% | 5.98 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 70.43-61.3% | 181.82-31.9% | 266.97+41.4% | 188.78-16.2% | 225.18+491.6% | 38.06+536.5% | 5.98 |
| Total Liabilities & Stockholders Equity | 123.00-48.5% | 238.99-22.9% | 310.12+57.7% | 196.59-14.6% | 230.33+418.4% | 44.43+507.0% | 7.32 |
| Book Value Per Share per share | 1.16-61.7% | 3.03-34.3% | 4.61+0.2% | 4.60-17.3% | 5.56 | -0.46 | -0.28 |
| Tangible Book Value Per Share per share | 1.16-61.7% | 3.03-34.3% | 4.61+0.2% | 4.60-17.3% | 5.56 | -0.46 | -0.28 |
| Full-Time Employees people | 610.0% | 61+17.3% | 52+30.0% | 40+135.3% | 17+142.9% | 7 | - |
| Price to Book Ratio ratio | 0.46 | 0.48 | 0.79 | 1.11 | 1.22 | 1.20 | - |
| Return on Assets % | -67.04 | -37.27 | -20.67 | -20.08 | -73.23 | -28.31 | - |
| Return on Equity % | -96.20 | -45.60 | -22.98 | -20.71 | -76.44 | -33.26 | - |
| Return on Invested Capital % | -130.71 | -48.41 | -17.62 | -22.70 | -44.68 | -19.24 | -132.22 |
| Quick Ratio ratio | 4.07 | 6.46 | 19.01 | 23.08 | 38.60 | 6.98 | 5.35 |
| Current Ratio ratio | 4.07 | 6.46 | 19.01 | 23.08 | 38.60 | 6.98 | 5.35 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -103.96 | -121.33 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | -7.91 |
| Depreciation | 0.18 | 0.180.0% | 0.180.0% | 0.18+5.9% | 0.17 | 0.00 | - | - |
| Other Funds (Non Cash) | 10.52 | 10.73+150.7% | 4.28-18.6% | 5.26+48.2% | 3.55-95.7% | 82.34 | -0.43-234.4% | 0.32 |
| Funds from Operations | -93.25 | -110.42 | -97.87 | -46.93 | -39.14 | -18.26 | -7.76 | -7.59 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 5.30 | -5.12-143.9% | 11.65+201.0% | 3.87-3.0% | 3.99+1230.0% | 0.30-3.2% | 0.31-59.7% | 0.77 |
| Cash from Operating Activities | -87.95 | -115.54 | -86.22 | -43.06 | -35.15 | -17.96 | -7.45 | -6.82 |
| Capital Expenditures | 0.00 | -0.09 | -0.02 | -0.02 | -0.16 | -0.04 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 63.69 | 134.02+179.0% | 48.04 | -171.65-536.2% | 39.35 | -104.08 | 0.00 | 0.00 |
| Purchase of Investments | -40.82 | -38.06 | -170.73 | -250.63 | -41.51 | -104.08 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 104.52 | 172.08-21.3% | 218.77+177.0% | 78.98-2.3% | 80.86 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 63.69 | 133.93+178.8% | 48.03 | -171.67-538.0% | 39.19 | -104.12 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 35.49 | -0.03-100.4% | 7.67-93.7% | 122.23+3026.1% | 3.91-98.0% | 200.47+348.8% | 44.67+615.9% | 6.24 |
| Repurchase of Common Pref Stock | -0.15 | -0.07 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 35.64 | 0.04-99.5% | 7.71-93.7% | 122.23+3026.1% | 3.91-98.0% | 200.47+348.8% | 44.67+615.9% | 6.24 |
| Proceedsfrom Stock Options | 35.44 | 0.00-100.0% | 7.71-93.7% | 121.90+3116.4% | 3.79-98.1% | 198.59+344.6% | 44.67+617.0% | 6.23 |
| Issuance or Reduction of Debt, Net | -4.99 | 0.00 | -0.74-102.5% | 29.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -4.99 | 0.00 | -0.74-102.5% | 29.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00-100.0% | 29.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -4.99 | 0.00 | -0.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 30.50 | -0.03-100.4% | 6.93-95.4% | 151.75+3781.1% | 3.91-98.0% | 200.47+348.8% | 44.67+615.9% | 6.24 |
| Net Change in Cash | 6.24 | 18.36 | -31.26 | -62.98-893.2% | 7.94-89.9% | 78.39+110.6% | 37.23 | -0.58 |
| Free Cash Flow | -87.95 | -115.63 | -86.23 | -43.09 | -35.31 | -18.00 | -7.45 | -6.82 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 78.60-37.9% | 110.20-23.1% | 128.40-13.9% | 116.86-31.9% | 126.61-36.8% | 143.37-45.0% | 149.15-40.9% | 171.56-29.5% |
| Short Term Receivables | 1.75+360.5% | 1.00+212.5% | 0.77+102.6% | 0.62+55.0% | 0.38+18.8% | 0.32+190.9% | 0.38+100.0% | 0.40+73.9% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.78-7.5% | 4.31-8.7% | 3.92-27.7% | 4.76-25.0% | 5.17-25.8% | 4.72-25.6% | 5.42+73.2% | 6.35+121.3% |
| Total Current Assets | 85.13-35.6% | 115.51-22.2% | 133.09-14.1% | 122.25-31.4% | 132.15-36.4% | 148.40-44.4% | 154.95-39.4% | 178.31-27.7% |
| Net Property, Plant & Equipment | 0.10-65.5% | 0.15-55.9% | 0.20-45.9% | 0.24-29.4% | 0.29-25.6% | 0.34-20.9% | 0.37-21.3% | 0.34-32.0% |
| Total Investments and Advances | 0.23-97.6% | 0.23-99.0% | 0.23-99.5% | 0.23-99.6% | 9.68-83.5% | 23.03+8.9% | 49.03+10.6% | 60.20-4.1% |
| Deferred Tax Assets | - | - | - | 0.16 | - | - | - | - |
| Other Assets | 0.100.0% | 0.11-15.4% | 0.11-15.4% | 0.11-26.7% | 0.10-41.2% | 0.13-69.0% | 0.13-59.4% | 0.15-31.8% |
| Total Assets | 85.56-39.8% | 116.01-32.5% | 133.63-34.6% | 123.00-48.5% | 142.22-46.7% | 171.90-40.5% | 204.48-32.1% | 238.99-22.9% |
| Short Term Debt Incl. Current Port. of LT Debt | 20.44+446.5% | 19.75+14007.1% | 14.24+10071.4% | 8.91+6753.8% | 3.74+2776.9% | 0.14+16.7% | 0.14+16.7% | 0.13-85.1% |
| Accounts Payable | 6.06+791.2% | 13.38+537.1% | 1.66+56.6% | 0.55-90.3% | 0.68-70.9% | 2.10-50.1% | 1.06-65.6% | 5.65+309.4% |
| Other Current Liabilities | 18.59+6.0% | 13.72-39.3% | 13.34-26.4% | 20.54-5.9% | 17.53+0.5% | 22.62+105.1% | 18.12+243.8% | 21.83+103.4% |
| Total Current Liabilities | 45.09+105.3% | 46.85+88.5% | 29.23+51.3% | 30.01+8.7% | 21.96+10.3% | 24.86+61.7% | 19.32+128.1% | 27.61+112.9% |
| Long Term Debt | 5.87-78.3% | 11.90-60.3% | 16.92-42.9% | 22.40-24.2% | 27.09-9.3% | 29.96+1.2% | 29.64-2.7% | 29.57-2.0% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 0.16 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 50.95+3.9% | 58.74+7.2% | 46.15-5.7% | 52.57-8.1% | 49.05-1.4% | 54.82+21.9% | 48.96+25.8% | 57.18+32.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 34.61-62.9% | 57.26-51.1% | 87.48-43.8% | 70.43-61.3% | 93.17-57.1% | 117.08-52.0% | 155.52-40.6% | 181.82-31.9% |
| Total Shareholders Equity | 34.61-62.9% | 57.26-51.1% | 87.48-43.8% | 70.43-61.3% | 93.17-57.1% | 117.08-52.0% | 155.52-40.6% | 181.82-31.9% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 34.61-62.9% | 57.26-51.1% | 87.48-43.8% | 70.43-61.3% | 93.17-57.1% | 117.08-52.0% | 155.52-40.6% | 181.82-31.9% |
| Total Liabilities & Stockholders Equity | 85.56-39.8% | 116.01-32.5% | 133.63-34.6% | 123.00-48.5% | 142.22-46.7% | 171.90-40.5% | 204.48-32.1% | 238.99-22.9% |
| Book Value Per Share per share | 0.48-68.8% | 0.79-59.1% | 1.21-52.9% | 1.16-61.7% | 1.54-57.5% | 1.93-52.5% | 2.57-41.1% | 3.03-34.3% |
| Tangible Book Value Per Share per share | 0.48-68.8% | 0.79-59.1% | 1.21-52.9% | 1.16-61.7% | 1.54-57.5% | 1.93-52.5% | 2.57-41.1% | 3.03-34.3% |
| Full-Time Employees people | - | - | - | 610.0% | - | - | - | 61+17.3% |
| Price to Book Ratio ratio | 0.46 | 2.20 | 2.03 | 1.37 | 0.88 | 0.45 | 0.36 | 0.48 |
| Return on Assets % | -91.28 | -72.97 | -67.01 | -67.04 | -65.18 | -59.32 | -46.00 | -37.27 |
| Return on Equity % | -162.72 | -120.50 | -93.23 | -96.20 | -85.93 | -75.71 | -55.68 | -45.60 |
| Return on Invested Capital % | -62.67 | -47.31 | -19.86 | -27.08 | -21.99 | -27.85 | -15.55 | -17.58 |
| Quick Ratio ratio | 1.89 | 2.47 | 4.55 | 4.07 | 6.02 | 5.97 | 8.02 | 6.46 |
| Current Ratio ratio | 1.89 | 2.47 | 4.55 | 4.07 | 6.02 | 5.97 | 8.02 | 6.46 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -25.37 | -32.72 | -20.74 | -25.14 | -26.45 | -40.95 | -28.80 | -37.15 |
| Depreciation | 0.050.0% | 0.04-20.0% | 0.05+25.0% | 0.040.0% | 0.05+25.0% | 0.05+25.0% | 0.040.0% | 0.040.0% |
| Other Funds (Non Cash) | 2.36-19.7% | 2.86+2.1% | 2.30+15.6% | 3.00+79.6% | 2.94+111.5% | 2.80+1455.6% | 1.99+91.3% | 1.67-20.1% |
| Funds from Operations | -22.96 | -29.81 | -18.39 | -22.09 | -23.46 | -38.11 | -26.76 | -35.44 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -3.69 | 11.74+86.9% | -5.74 | 2.99-63.6% | -7.03-288.5% | 6.28+66.6% | -7.36 | 8.22+35.9% |
| Cash from Operating Activities | -26.65 | -18.07 | -24.13 | -19.10 | -30.49 | -31.83 | -34.12 | -27.21 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.08 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 25.25-37.7% | 26.00-32.4% | -13.81-148.0% | 26.25-11.5% | 40.51 | 38.49+2.1% | 28.77 | 29.66 |
| Purchase of Investments | 0.00 | 0.00 | -40.82 | 0.00 | 0.00 | -3.01 | -35.05 | -15.10 |
| Sale Or Maturity of Investments | 25.25-37.7% | 26.00-37.3% | 27.02-57.7% | 26.25-41.4% | 40.51-54.2% | 41.50-16.2% | 63.82+76.8% | 44.76+94.8% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 25.25-37.7% | 26.00-32.4% | -13.81-148.1% | 26.25-11.5% | 40.51 | 38.48+2.1% | 28.69 | 29.66 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.02 | -0.28 | 35.74 | 0.00 | 0.00 | 0.00 | -0.04-100.5% | -0.01 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | -0.15 | 0.00 | 0.00 | 0.00 | -0.07 | -0.01 |
| Sale of Common Pref Stock | 0.02 | -0.28 | 35.89+89625.0% | 0.00 | 0.00 | 0.00 | 0.04-99.5% | 0.00 |
| Proceedsfrom Stock Options | 0.00 | -0.30 | 35.75+89275.0% | 0.00 | -0.04 | 0.00 | 0.04-99.5% | 0.00 |
| Issuance or Reduction of Debt, Net | -4.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.74-102.5% |
| Change in Long Term Debt | -4.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.74-102.5% |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Reduction of Long Term Debt | -4.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.74 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -4.96 | -0.28 | 35.74 | 0.00 | 0.00 | 0.00 | -0.04-100.6% | -0.01-100.0% |
| Net Change in Cash | -6.37-163.6% | 7.65+15.0% | -2.19 | 7.16+193.4% | 10.02 | 6.65-68.4% | -5.47 | 2.44 |
| Free Cash Flow | -26.65 | -18.07 | -24.13 | -19.10 | -30.49 | -31.84 | -34.20 | -27.21 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 7.38% | 4.6M | 61.8M | 1.56M |
| 2026-10-15 | 5.00% | 3.1M | 61.8M | 441.24K |
| 2026-09-30 | 4.99% | 3.1M | 61.8M | 408.40K |
| 2026-09-15 | 4.54% | 2.8M | 61.8M | 473.40K |
| 2026-08-31 | 5.12% | 3.2M | 61.7M | 467.60K |
| 2026-08-14 | 5.22% | 3.2M | 61.7M | 462.92K |
| 2026-07-31 | 5.46% | 3.4M | 61.7M | 454.67K |
| 2026-07-15 | 4.56% | 2.8M | 61.7M | 450.35K |
| 2026-06-30 | 4.52% | 2.8M | 61.7M | 469.75K |
| 2026-06-15 | 3.06% | 1.9M | 61.7M | 535.07K |
| 2026-05-29 | 3.07% | 1.9M | 61.7M | 540.09K |
| 2026-05-15 | 2.83% | 1.7M | 61.7M | 532.07K |
| 2026-04-30 | 2.70% | 1.7M | 62.0M | 558.07K |
| 2026-04-15 | 2.84% | 1.5M | 54.4M | 892.85K |
| 2026-03-31 | 1.91% | 1.1M | 55.3M | 848.44K |
| 2026-03-13 | 2.23% | 1.0M | 46.4M | 623.93K |
| 2026-02-27 | 2.07% | 1.0M | 46.4M | 583.90K |
| 2026-02-13 | 2.04% | 0.9M | 46.4M | 566.10K |
| 2026-01-30 | 1.94% | 0.9M | 46.4M | 533.02K |
| 2026-01-15 | 1.29% | 0.6M | 46.3M | 213.33K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | 0.00 | 1.00 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 1.00 | 0.00 | 1.00 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 1.50 | 0.00 | 1.00 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 2.00 | 0.00 | 1.00 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 2.50 | 0.00 | 0.05 | 0.05 | 12.001 | 738 | 0.00 | 0.364 | -0.009 | 0.000 |
| call | 5.00 | 0.00 | 0.05 | 0.05 | 14.765 | 1,243 | 0.00 | 0.359 | -0.011 | 0.000 |
| call | 7.50 | 0.00 | 0.05 | 0.00 | 15.453 | 0.00 | 0.00 | 0.351 | -0.012 | 0.000 |
| put | 0.50 | 0.00 | 0.40 | 0.35 | 13.749 | 18.00 | 1.00 | -0.274 | -0.009 | 0.000 |
| put | 1.00 | 0.00 | 1.00 | 0.85 | 16.090 | 10.00 | 4.00 | -0.295 | -0.011 | 0.000 |
| put | 1.50 | 0.45 | 1.45 | 1.35 | 22.791 | 7.00 | 1.00 | -0.137 | -0.010 | 0.000 |
| put | 2.00 | 1.00 | 2.00 | 1.85 | 0.000 | 13.00 | 4.00 | 0.000 | 0.000 | 0.000 |
| put | 2.50 | 1.50 | 2.50 | 2.35 | 0.000 | 47.00 | 1.00 | -0.626 | -0.010 | 0.000 |
| put | 5.00 | 4.00 | 5.00 | 4.85 | 0.000 | 14.00 | 1.00 | -0.641 | -0.011 | 0.000 |
| put | 7.50 | 6.50 | 7.50 | 7.35 | 0.000 | 13.00 | 8.00 | -0.649 | -0.011 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-05 | 8-K | Current report | 2026-11-01 | SEC |
| 2026-10-30 | 8-K | Current report | 2026-10-30 | SEC |
| 2026-10-28 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-10-26 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-10-26 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-10-26 | 8-K | Current report | 2026-10-26 | SEC |
| 2026-09-16 | 8-K | Current report | 2026-09-16 | SEC |
| 2026-08-12 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-12 | 8-K | Current report | 2026-08-12 | SEC |
| 2026-06-17 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-15 | SEC |
| 2026-06-16 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-16 | 8-K | Current report | 2026-06-12 | SEC |
| 2026-06-15 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-03 | SEC |
| 2026-06-03 | 8-K | Current report | 2026-06-03 | SEC |
| 2026-05-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-12 | 8-K | Current report | 2026-05-12 | SEC |
| 2026-04-23 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-23 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 89.51K | 4 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 6.81K | 1 |
| 2026-02 | 0 | 0 | 28.31K | 1 |
| 2026-01 | 0 | 0 | 500.79K | 38 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 29.06% |
| Sands Capital Alternatives, LLC | 5.15% |
| BlackRock, Inc. | 3.45% |
| Alyeska Investment Group, L.P. | 3.40% |
| FRANKLIN TEMPLETON INC | 3.19% |
| ADAR1 Capital Management, LLC | 2.92% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.32% |
| Knollwood Investment Advisory, LLC | 2.25% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.60% |
| Ikarian Capital, LLC | 1.46% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.55% |
| iShares Russell 2000 ETF | 1.43% |
| Franklin Biotechnology Discovery Fund | 1.14% |
| Fidelity Small Cap Index Fund | 0.71% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.71% |
| iShares Russell 2000 Value ETF | 0.60% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.37% |
| Fidelity Extended Market Index Fund | 0.32% |
| iShares Micro-Cap ETF | 0.22% |
| Schwab Small-Cap Index Fund | 0.16% |
OakChart. ABOS. Cached 15 minutes. Terms